Actavalon is an oncology-focused company targeting two fundamental cancer pathways – the p53 tumor suppressor pathway and the Aryl Hydrocarbon Receptor (AhR) pathway.

Actavalon was incorporated in 2013 with scientific founders from UCI and UCSD, leveraging over $6 million in university NIH grants. The company is currently located in the JLABS incubator on the Johnson & Johnson Innovation Labs campus in San Diego.